Overview

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Retro Biosciences operates three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. They utilize advanced technologies like single-cell multi-omics and computational biology to support their research. With $180 million in funding, Retro Biosciences aims to achieve proofs of concept for its treatments, positioning itself to make significant contributions to age-related disease prevention.

Simplify's Take

What believers are saying

• Retro Biosciences secured $1 billion in funding to support its longevity mission.
• Partnerships with MCRI and Multiply Labs enhance therapeutic development and manufacturing capabilities.
• Growing interest in personalized medicine aligns with Retro's focus on autologous cell therapies.

What critics are saying

• Intensifying competition in the longevity biotech sector may impact funding and partnerships.
• Public and regulatory scrutiny of anti-aging therapies could lead to stricter regulations.
• Reliance on large funding rounds poses financial risks if market conditions change.

What makes Retro Biosciences unique

• Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
• The company aims to extend healthy human lifespan by ten years.
• Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.

Help us improve and share your feedback! Did you find this helpful?

YesNo